The upgrade from Needham is a positive signal for Hologic. It indicates that the analyst believes the company's stock is likely to outperform in the future. The price target of $95 also suggests a significant upside potential from the current price level. This could lead to increased buying interest in the stock, potentially driving its price up in the short term.